drugset
drugset / Trial / NCT05573568

Clinical Study of DMT in Healthy Adults

NCT05573568 ↗

Phase 1 Completed 27 enrolled Biomind Labs Inc. Universidade Federal do Rio Grande do Norte · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine in healthy individuals.

Timeline

Start
2022-06-01
Primary completion
2022-11-01
Completion
2022-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject N,N-Dimethyltryptamine Unknown 20 mg Inhaled
Subject N,N-Dimethyltryptamine Unknown 30 mg Inhaled
Subject N,N-Dimethyltryptamine Unknown 40 mg Inhaled
Subject N,N-Dimethyltryptamine Unknown 50 mg Inhaled
Subject N,N-Dimethyltryptamine Unknown 60 mg Inhaled

Indications

No indication recorded.